Literature DB >> 7849741

The molecular genetics of tuberous sclerosis.

J R Sampson1, P C Harris.   

Abstract

Tuberous sclerosis (TSC) is an autosomal dominant trait characterized by the widespread development of benign tumours classified as hamartoma, and is often associated with seizures and mental retardation. The patchy distribution and focal nature of the growths suggests that they might result from inactivation of a tumour suppressor gene by a two-hit process. Over the last 2 years, studies designed to investigate both germline and somatic TSC mutations have lent support to this hypothesis. Analysis of TSC-associated hamartomas has shown loss of heterozygosity for the regions of chromosomes 9 and 16 known to harbour TSC genes, consistent with the occurrence of somatic 'second-hit' mutations. Parallel investigations using pulse field gel electrophoresis have identified constitutional deletions representing 'first-hit' mutations at 16p13.3, leading to the rapid identification of one of the causative genes, TSC2. Intriguingly, the TSC2 product, tuberin, has an area of sequence homology with the GTPase activating protein rap1GAP, suggesting a possible mechanism for its role in regulating cellular growth.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7849741     DOI: 10.1093/hmg/3.suppl_1.1477

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  20 in total

Review 1.  Neurological manifestations of tuberous sclerosis complex.

Authors:  P Curatolo
Journal:  Childs Nerv Syst       Date:  1996-09       Impact factor: 1.475

2.  Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2.

Authors:  T Soucek; R S Yeung; M Hengstschläger
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

3.  Expression and differential splicing of the mouse TSC2 homolog.

Authors:  P G Olsson; J N Schofield; Y H Edwards; A M Frischauf
Journal:  Mamm Genome       Date:  1996-03       Impact factor: 2.957

4.  Involvement of lymphatics in lymphangioleiomyomatosis.

Authors:  Connie G Glasgow; Angelo Taveira-DaSilva; Gustavo Pacheco-Rodriguez; Wendy K Steagall; Katsuya Tsukada; Xiong Cai; Souheil El-Chemaly; Joel Moss
Journal:  Lymphat Res Biol       Date:  2009-12       Impact factor: 2.589

5.  Sporadic lymphangioleiomyomatosis and tuberous sclerosis complex with lymphangioleiomyomatosis: comparison of CT features.

Authors:  Nilo A Avila; Andrew J Dwyer; Antoinette Rabel; Joel Moss
Journal:  Radiology       Date:  2006-11-14       Impact factor: 11.105

6.  Familial hemiplegic migraine in the west of Scotland: a clinical and genetic study of seven families.

Authors:  M A Ahmed; E Reid; A Cooke; R Arngrímsson; J L Tolmie; J B Stephenson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-12       Impact factor: 10.154

7.  Aggressive retinal astrocytomas in four patients with tuberous sclerosis complex.

Authors:  Jerry A Shields; Ralph C Eagle; Carol L Shields; Brian P Marr
Journal:  Trans Am Ophthalmol Soc       Date:  2004

Review 8.  A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits.

Authors:  David M Feliciano; Tiffany V Lin; Nathaniel W Hartman; Christopher M Bartley; Cathryn Kubera; Lawrence Hsieh; Carlos Lafourcade; Rachel A O'Keefe; Angelique Bordey
Journal:  Int J Dev Neurosci       Date:  2013-02-26       Impact factor: 2.457

9.  Expression of the neural stem cell markers NG2 and L1 in human angiomyolipoma: are angiomyolipomas neoplasms of stem cells?

Authors:  So Dug Lim; William Stallcup; Benjamin Lefkove; Baskaran Govindarajan; Kit Sing Au; Hope Northrup; Deborah Lang; David E Fisher; Avani Patel; Mahul B Amin; Jack L Arbiser
Journal:  Mol Med       Date:  2007 Mar-Apr       Impact factor: 6.354

Review 10.  Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment.

Authors:  Bing-Hua Jiang; Ling-Zhi Liu
Journal:  Drug Resist Updat       Date:  2008-04-28       Impact factor: 18.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.